Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,730.00
Bid: 1,729.50
Ask: 1,730.50
Change: 1.50 (0.09%)
Spread: 1.00 (0.058%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: FTSE 100 at three-week high after policy meetings

Thu, 05th Sep 2013 17:03

A host of central-bank policy meetings, a dovish tone from Mario Draghi and the continued improvement in US economic data helped lift stocks higher on Thursday, with the FTSE 100 closing at levels not seen in three weeks.London's benchmark index ended the day up 57.7 points at 6,532.44, its highest level since August 14th when it finished at 6,587.43."European equities are enjoying the continued central-bank activism of low interest rates environment sticking around for the foreseeable future," said Market Strategist Ishaq Siddiqi from ETX Capital.The Bank of Japan, Bank of England and European Central Bank (ECB) all decided to keep interest rates on hold and current stimulus measures in place on Thursday. However, stocks extended gains in the afternoon after ECB President Mario Draghi struck a dovish tone in a press conference following the bank's decision, saying that the Governing Council had even discussed a rate cut at this month's meeting but decided against it. Draghi did however raise his expectations for Eurozone growth for this year.A barrage of US economic data came in better than expected this afternoon, supporting the call for the Federal Reserve to begin tapering asset purchases at its next meeting later this month - jobless claims fell more than forecasts, factory orders declined less than expected and the ISM non-manufacturing index smashed estimates.However, given that the Fed has explicitly said that the labour market is a key factor in its decision, analysts will be watching the August employment report - due out on Friday afternoon - very carefully. Consensus estimates are for a 180,000 increase in non-farm payrolls last month, up from the 162,000 gain in July. The unemployment rate is expected to remain unchanged at 7.4%, though this has already fallen speedily from 7.9% in January.Meanwhile, the G20 meeting which began in St Petersburg today was likely on the back of investors' minds, given that a potential US military strike in Syria is expected to be the hot topic amongst world leaders. Michael Hewson, Senior Market Analyst at CMC Markets, said: "while there may not be much in the way of fireworks we could well see a lot of tension, given the opposing views of the US and Russia, over the rationale for any type of intervention."FTSE 100: M&S leaps after HSBC upgradeHigh Street department store Marks & Spencer surged today after HSBC upgraded the stock from 'neutral' to 'overweight', saying it is the most operationally geared among its peers to play on the UK consumer recovery.Hotels group IHG was also a high riser after UBS raised its rating from 'neutral to 'buy' and added the stock to its 'Most Preferred' list. The Swiss bank highlighted alleviated concerns about pipeline after the company added more rooms in the first half and also pointed to improving growth in China and continued strength in the US.Decent August traffic statistics from airline peers easyJet and IAG over the last 24 hours have helped both stocks rebound today after falling heavily yesterday on the back of a profit warning from Ryanair, Europe's largest low-cost carrier.Banks were also performing well with Lloyds, Standard Chartered, HSBC, RBS and Barclays all registering decent gains. Lloyds was being helped higher by reports that the Treasury could delay the sale of its 39% stake until later this year because of ongoing tensions in the Middle East and the Fed's taper plan.Meanwhile, food groups Tate & Lyle and AB Foods were lower after Credit Suisse highlighted concerns about sugar prices falling sooner and more steeply than expected.Pharmaceuticals group GlaxoSmithKline was also in the red after announcing a setback on its potential new skin-cancer treatment during clinical trials.FTSE 100 - RisersPersimmon (PSN) 1,152.00p +3.69%Marks & Spencer Group (MKS) 494.90p +3.38%ITV (ITV) 174.60p +3.07%Lloyds Banking Group (LLOY) 74.77p +2.95%International Consolidated Airlines Group SA (CDI) (IAG) 299.40p +2.89%Kingfisher (KGF) 405.80p +2.86%GKN (GKN) 346.60p +2.70%Standard Chartered (STAN) 1,472.50p +2.58%Wolseley (WOS) 3,383.00p +2.52%Rolls-Royce Holdings (RR.) 1,147.00p +2.50%FTSE 100 - FallersTate & Lyle (TATE) 799.50p -1.60%Croda International (CRDA) 2,607.00p -1.25%GlaxoSmithKline (GSK) 1,652.50p -0.81%British Sky Broadcasting Group (BSY) 851.50p -0.76%Associated British Foods (ABF) 1,829.00p -0.65%G4S (GFS) 254.40p -0.62%Antofagasta (ANTO) 881.00p -0.56%Bunzl (BNZL) 1,365.00p -0.44%Aggreko (AGK) 1,599.00p -0.37%Admiral Group (ADM) 1,260.00p -0.32%FTSE 250 - RisersICAP (IAP) 400.00p +6.70%Dixons Retail (DXNS) 46.88p +5.92%Supergroup (SGP) 1,227.00p +5.87%Imagination Technologies Group (IMG) 279.30p +5.68%Tullett Prebon (TLPR) 382.40p +5.29%Home Retail Group (HOME) 152.50p +5.03%Halfords Group (HFD) 381.00p +4.01%Rentokil Initial (RTO) 107.50p +3.97%Hochschild Mining (HOC) 277.90p +3.89%Galliford Try (GFRD) 1,015.00p +3.73%FTSE 250 - FallersBumi (BUMI) 213.40p -2.87%Countrywide (CWD) 550.00p -2.65%BH Macro Ltd. EUR Shares (BHME) € 20.62 -2.51%Rank Group (RNK) 153.10p -2.48%Dairy Crest Group (DCG) 490.60p -2.17%Ted Baker (TED) 1,920.00p -2.14%esure Group (ESUR) 228.50p -1.93%International Public Partnerships Ltd. (INPP) 128.60p -1.83%NMC Health (NMC) 323.00p -1.79%Enterprise Inns (ETI) 143.40p -1.71%BC
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.